News | September 13, 2013

FDA Committee Reviews Innovative CardioMEMS Heart Failure Monitor

Panel also reviews Medtronic ICD expansion for heart failure

CardioMEMs

September 13, 2013 – The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee will review two new technologies to help treat heart failure (HF) Oct. 8-9, 2013.

On Oct. 9, the committee will discuss, make recommendations and vote on information related to the premarket approval application for CardioMEMS Inc. Champion HF monitoring system. The system is a permanently implantable pressure measurement system designed to provide daily pulmonary arterial pressure measurements including systolic, diastolic and mean pulmonary arterial (PA) pressure. These measurements are used to guide treatment of congestive heart failure.

The system consists of an implantable sensor containing a three- dimensional coil and pressure-sensitive capacitor encased between two wafers of fused silica. The coil (inductor) electromagnetically couples to the sensor and allows the remote measurement of the resonant frequency of the inductive/capacitive circuit. This allows for wireless communication with the sensor and eliminates the need for an onboard source of energy, such as a battery. 

The device is delivered within the distal pulmonary artery. There are two versions of the delivery system. The first includes a hydrophilic coating on the distal portion of the catheter shaft and the second has no coating on the catheter shaft. The delivery system (with HF sensor) is introduced over a guidewire through a sheath. Tether wires connect the sensor to the delivery system until the physician determines that the sensor is properly positioned within the distal pulmonary artery. Once the sensor is in position, the tether wires are withdrawn, releasing the sensor.

The electronics unit (interrogator) and database contain hardware and software to acquire and process signals from the sensor, provides a system interface for both patients and clinicians, and transfers PA measurements to a database for review by medical professionals. The database is a Web-based server that contains software, which receives data transmitted from the electronics unit, and presents the data for review by medical professionals.    

On Oct. 8, the committee will review and make recommendations related to the expansion of heart failure indications to all market-approved Medtronic cardiac resynchronization therapy-pacemaker and cardiac resynchronization therapy-defibrillator devices.

The requested expansion in indications for use was studied under the Block HF trial. The trial was a prospective, multisite, randomized, double-blinded, parallel-controlled investigational device exemption study. The primary objective of the trial was to demonstrate that the time until the first event of all-cause mortality, heart-failure- related urgent care, or a significant increase in left ventricular end systolic volume index for subjects programmed to biventricular pacing is superior to that of subjects programmed to right ventricular pacing.     

The meeting will be held each day from 8 a.m. to 6 p.m. at the Hilton Washington, D.C., North/Gaithersburg, Salons A-D, 620 Perry Pkwy., Gaithersburg, Md.

For more information: www.fda.gov/AdvisoryCommittees/Calendar/default.htm

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Overlay Init